(SIGA) Volatility Zones as Tactical Triggers
This article provides an AI-driven analysis of Siga Technologies Inc. (NASDAQ: SIGA), highlighting strong near-term sentiment with a long-term positive bias. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—along with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal insights and offers access to real-time signals and personalized alerts.
SIGA Technologies Inc. (SIGA) Stock Analysis: Decoding the Investment Potential in Healthcare’s Niche Sector
SIGA Technologies Inc. specializes in antiviral treatments, with TPOXX for smallpox as its flagship product, operating in the health security market. Despite a significant revenue growth decline of 73.80%, the company boasts a strong return on equity of 39.94% and considerable free cash flow. While there's an absence of analyst coverage, SIGA's strategic market position and innovative products present a unique opportunity for investors willing to conduct their own due diligence.
Price-Driven Insight from (SIGA) for Rule-Based Strategy
This report provides a price-driven analysis for Siga Technologies Inc. (NASDAQ: SIGA), indicating a neutral near and mid-term sentiment but a positive long-term bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with support and resistance levels across different time horizons. The analysis highlights an exceptional risk-reward setup with a potential 21.1% gain.
Stock Traders Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)
Stock traders recently bought an unusually large volume of call options on Siga Technologies (NASDAQ:SIGA), with 1,200 calls purchased, representing a 1,438% increase over its average daily volume. The company, a specialty pharmaceutical firm known for its antiviral TPOXX, trades near $6.73, has a market cap of $482 million, and recently reported a quarterly EPS loss. Despite institutional investors owning 55.4% of shares, analysts currently rate the stock as "Sell."
(SIGA) Price Dynamics and Execution-Aware Positioning
Siga Technologies Inc. (NASDAQ: SIGA) shows strong sentiment across all horizons, leading to an overweight bias. The article details an exceptional 66.5:1 risk-reward setup targeting a 20.8% gain, with current signals highlighting a mid-channel oscillation pattern. Three distinct AI-generated trading strategies are provided, catering to different risk profiles and holding periods, alongside a multi-timeframe signal analysis.
Lobbying Update: $80,000 of SIGA TECHNOLOGIES lobbying was just disclosed
SIGA Technologies recently disclosed $80,000 in lobbying expenditures for Q4 2025, focusing on "Biodefense funding." This update also highlights significant hedge fund activity, with some institutional investors increasing their holdings in SIGA stock while others reduced their positions.
Siga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for Investors
Siga Technologies Inc. (SIGA) saw its stock decline by -1.63% on a day when the broader market improved. Despite this, the company's shares have risen by 0.36% over the past month, outperforming the Medical sector. Analysts anticipate earnings of $0.13 per share and revenue of $184.36 million for the full year, while the stock currently holds a Zacks Rank of #4 (Sell) and trades at a premium to its industry peers.
(SIGA) as a Liquidity Pulse for Institutional Tactics
The article provides a detailed analysis of Siga Technologies Inc. (NASDAQ: SIGA) for institutional tactics, indicating weak near-term sentiment but strong mid- and long-term outlooks. It highlights an exceptional risk-reward setup with a target gain of 20.8% and outlines specific AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The piece also promotes access to real-time signals and personalized alerts for ongoing analysis.
Is SIGA Technologies’ (SIGA) TPOXX Cash Machine Reinforcing a Deep-Value Biodefense Narrative?
SIGA Technologies is presented as a deep-value biodefense company due to its profitable TPOXX antiviral franchise, strong balance sheet, and government contracts. While it generates substantial free cash flow and pays special dividends, its investment narrative heavily relies on the procurement timing and expansion of its single product, TPOXX. Investors should understand the risks associated with this product concentration and policy dependency.
Assessing SIGA Technologies (SIGA) Valuation As Biodefense Strength Draws Renewed Investor Attention
SIGA Technologies (SIGA) is gaining investor attention due to its TPOXX smallpox antiviral, consistent profitability, and strong balance sheet. Despite recent share price momentum, the company trades at a low Price-to-Earnings (P/E) ratio of 6.5x, suggesting undervaluation compared to peers and its intrinsic fair P/E of 28.2x, according to Simply Wall St. A Discounted Cash Flow (DCF) model further indicates a significant undervaluation, with an estimated fair value of around US$99.60 per share against its current US$6.77.
Deep Value Biodefense Pharmaceutical Company – SIGA Technologies Inc (SIGA)
SIGA Technologies Inc. is presented as a deeply undervalued biodefense pharmaceutical company with a highly profitable antiviral franchise. The company boasts a fortress balance sheet, significant free cash flow, and exceptional valuation metrics, including an IV/P of 3.90 and an Acquirer's Multiple of 3.01. Despite perceptions of single-product dependence and lumpy government procurement, the article argues that the market is mispricing SIGA's intrinsic worth given its strong financial performance and dominant niche.
Discovering Undiscovered Gems in the US Market December 2025
This article highlights promising small-cap stocks in the U.S. market during a holiday-shortened week in December 2025, offering investors opportunities for growth. It identifies companies with strong fundamentals, including SIGA Technologies, Agora, and Ennis, providing an overview of their operations and financial performance. The report encourages investors to explore these "undiscovered gems" for potential long-term gains.
Traders Purchase Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)
Traders have shown significant bullish interest in Siga Technologies (NASDAQ:SIGA), purchasing an unusually high volume of call options—1,200 calls, a 1,438% increase over the typical daily volume. Despite this heightened trading activity, analyst sentiment for the company remains muted, with an average "Hold" rating from Wall Street. Siga Technologies, known for its FDA-approved antiviral TPOXX and government contracts, currently has a market capitalization of $449 million, a P/E of 6.14, and substantial institutional ownership.
Trading the Move, Not the Narrative: (SIGA) Edition
This article provides a technical analysis of Siga Technologies Inc. (NASDAQ: SIGA), highlighting a near-term neutral sentiment amidst mid and long-term strength. It presents institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis to guide potential trading decisions. The analysis suggests a potential stall followed by expected lower levels if a current breakdown continues.
Responsive Playbooks and the SIGA Inflection
This article discusses the "Responsive Playbooks and the SIGA Inflection" for Siga Technologies Inc. (NASDAQ: SIGA). It highlights strong sentiment supporting an overweight bias, outlines institutional trading strategies including position, momentum breakout, and risk hedging, and offers multi-timeframe signal analysis. The article concludes by inviting users to access real-time signals and personalized analysis through a free account.
Market Cool On SIGA Technologies, Inc.'s (NASDAQ:SIGA) Earnings Pushing Shares 26% Lower
SIGA Technologies' shares have dropped 26% in the last month, contributing to a 11% decline over the past year. Despite a low P/E ratio of 6x, the company's earnings have fallen by 14% over the last year and 30% over three years. Although the sole analyst predicts 18% growth, on par with the market, investors remain unconvinced, suggesting potential unobserved threats to earnings.
Siga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)
Siga Technologies (NASDAQ:SIGA) experienced unusually high options trading volume, with traders buying 1,200 call options on Wednesday, a 1,438% increase from typical daily volume. This surge in activity comes as institutional investors have significantly increased their stakes in the company, which now owns 55.40% of the stock. Despite a consensus "Hold" rating from analysts and recent quarterly loss, analysts anticipate 1.04 EPS for the current fiscal year.
The past three years for SIGA Technologies (NASDAQ:SIGA) investors has not been profitable
SIGA Technologies shareholders have experienced a 35% decline in share price over the last three years, falling short of the market's 73% return. This underperformance aligns with an 11% annual drop in the company's earnings per share over the same period. Despite a recent sell-off, the long-term total shareholder return, including dividends, was -17%, suggesting that fundamental data indicating sustainable growth could make the current share price an opportunity for consideration.
Take Care Before Jumping Onto SIGA Technologies, Inc. (NASDAQ:SIGA) Even Though It's 26% Cheaper
SIGA Technologies (NASDAQ:SIGA) shares have dropped 26% in the last month, contributing to a 3.5% decline over the past year. Despite a low P/E ratio of 5.8x, the company has experienced a 14% decline in earnings last year and a 30% fall over three years. Although analyst forecasts predict an 18% earnings growth for the next year, exceeding the broader market, the depressed share price suggests investor skepticism regarding these projections.
Siga Technologies Inc. $SIGA Shares Sold by Los Angeles Capital Management LLC
Los Angeles Capital Management LLC reduced its stake in Siga Technologies Inc. (NASDAQ:SIGA) by 43.7% in Q2, selling 124,744 shares and retaining 160,853 shares valued at approximately $1.05 million. Despite this, institutional and hedge fund ownership of SIGA stands at 55.40%, with other institutions like Hotchkis & Wiley Capital Management LLC increasing their positions. The company, trading around $6.21 with a market cap of $444.7M, recently reported earnings and holds an average analyst rating of "Hold."
Earnings call transcript: SIGA Technologies Q3 2025 sees stock slide post-earnings
SIGA Technologies (SIGA) reported strong Q3 2025 product sales of $86 million for the nine-month period, a significant increase from the previous year, yet its stock slid 3.08% post-earnings. The company maintains a robust cash balance of $172 million with no debt and is actively investing in TPOXX development for post-exposure prophylaxis and a pediatric formulation, targeting FDA submission for the PEP indication in 2026. Despite potential delays due to government procurement processes and regulatory challenges, SIGA remains optimistic about future international sales and its strategic position in the smallpox treatment market.
SIGA Technologies, Inc. (NASDAQ:SIGA) Q3 2025 Earnings Call Transcript
SIGA Technologies (NASDAQ:SIGA) reported its Q3 2025 earnings, highlighting strong financial health and continued progress in its mission to support government preparedness against smallpox outbreaks with its antiviral treatment, TPOXX. The company discussed ongoing engagement with the U.S. government for future procurement, progress on its pediatric formulation and post-exposure prophylaxis programs, and its confidence in TPOXX's efficacy amidst European Medicines Agency reviews. SIGA emphasized its strong balance sheet with $172 million in cash and no debt, underpinning its strategic initiatives and long-term shareholder value creation.
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025
SIGA Technologies, Inc. reported its financial results for the three and nine months ended September 30, 2025, generating $86 million in product revenues and $33 million in pre-tax operating income for the first nine months. The company continues to focus on securing new procurement contracts with the U.S. and international governments. Key achievements include significant TPOXX revenues from the U.S. Strategic National Stockpile, increased BARDA funding, and regulatory approval for TPOXX in Japan.
SIGA TECHNOLOGIES INC SEC 10-Q Report
SIGA Technologies Inc. has released its Q3 2025 Form 10-Q report, detailing financial performance and operational highlights. While Q3 2025 saw a decrease in total revenues and an operating loss compared to Q3 2024, year-to-date revenues and operating income significantly increased due to higher sales to the U.S. Government. The company also provided updates on its TPOXX® sales, manufacturing initiatives, and future R&D plans, including a target for a Supplemental NDA submission in 2026.
SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results
SIGA Technologies, Inc. announced that it will host a webcast and conference call on November 6, 2025, at 4:30 P.M. ET to provide a business update following the release of its third-quarter 2025 financial results. The call will feature Diem Nguyen, CEO, and Daniel Luckshire, CFO, and will be accessible via webcast and telephone. A replay will also be available for two weeks.
SIGA Technologies, Inc.'s (NASDAQ:SIGA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
SIGA Technologies' shares have surged 26% recently despite being down 6.9% over the last year. The company's P/E ratio of 7.4x is significantly lower than the broader market, driven by declining earnings and a projected future growth of only 1.7%, which lags the market's 14% forecast. Investors are cautious due to limited growth prospects, keeping the P/E ratio suppressed.
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
SIGA Technologies, Inc. announced it will host a webcast and conference call on August 5, 2025, to provide a business update following the release of its second-quarter 2025 results. CEO Diem Nguyen and CFO Daniel Luckshire will participate in the call. The event will be accessible via webcast on the company's website and via a conference call for both domestic and international callers.
Lobbying Update: $80,000 of SIGA TECHNOLOGIES lobbying was just disclosed
SIGA Technologies disclosed $80,000 in lobbying activity for Q3 2025, primarily focused on "Biodefense funding." The article also details recent hedge fund activity in SIGA stock, with several institutions adding or removing significant shareholdings.
Siga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to Know
Siga Technologies Inc. (SIGA) saw its stock decline by -1.4% to $7.06, underperforming the broader market despite a general uptick. The company's stock has risen 11.18% over the past month, and investors are anticipating its upcoming earnings report, with analysts expecting an 84.15% decrease in EPS but a 32.97% increase in revenue year-over-year. SIGA currently holds a Zacks Rank of #3 (Hold) and is trading at a premium Forward P/E of 55.08 compared to its industry average.
Stock Traders Purchase Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)
Stock traders have bought a significant volume of call options on Siga Technologies (NASDAQ:SIGA), indicating bullish sentiment. The company recently saw its stock price increase by 0.6% and has attracted institutional investment, with various firms adjusting their holdings. Siga Technologies specializes in an oral antiviral drug for smallpox.
SIGA Technologies, Inc.'s (NASDAQ:SIGA) Shares Bounce 26% But Its Business Still Trails The Market
This article analyzes SIGA Technologies, Inc.'s stock performance, noting a 26% bounce despite its business lagging the broader market. It suggests that while there has been recent positive momentum, investors should consider the company's underlying business health relative to market trends.
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025
SIGA Technologies, Inc. announced strong financial results for the three and six months ended June 30, 2025, reporting product revenues of $79 million for the quarter. The company also secured an additional $27 million in development funding under the BARDA 19C contract, reflecting significant progress in its TPOXX pediatric program and manufacturing support. These achievements highlight the company's robust business model and the continued value of its TPOXX antiviral treatment for smallpox.
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025
SIGA Technologies announced its financial results for the three and six months ended June 30, 2025, reporting significant product revenues of $79 million for the quarter and $84.9 million for the six months. The company also secured an additional $27 million in BARDA 19C contract development funding during the second quarter. Key highlights include TPOXX sales to the Strategic National Stockpile and increased funding for pediatric development and manufacturing support.
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
SIGA Technologies, Inc. announced it will host a business update webcast and conference call on Tuesday, August 5, 2025, at 4:30 P.M. ET, following the release of its second-quarter 2025 results. CEO Diem Nguyen and CFO Daniel Luckshire will participate in the call. A replay will be available for two weeks, and the webcast will be accessible through the company's investor relations website.
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
SIGA Technologies Inc. (SIGA) announced it will host a webcast and conference call on August 5, 2025, at 4:30 P.M. ET to provide a business update following the release of its second-quarter 2025 results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire, with details provided for live access and replay. The company, focused on infectious disease treatments like TPOXX®, aims to keep stakeholders informed of its progress.
TPOXXÒ (tecovirimat): Novel Antiviral Agent in the Event of a Smallpox Epidemic
This article discusses TPOXX (tecovirimat), a novel antiviral agent developed for the treatment of smallpox, especially in the event of a bioterror attack. Due to the eradication of naturally occurring smallpox, TPOXX's efficacy was evaluated using the FDA's "Animal Rule" through studies in non-human primates and rabbits, showing effectiveness and no safety concerns in human volunteers. The U.S. government has added 2 million doses to the Strategic National Stockpile, and further research is ongoing for an intravenous formulation and potential prophylactic use, as well as for other orthopoxviruses like monkeypox.
SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results
SIGA Technologies, Inc. (Nasdaq: SIGA) announced it will host a webcast and conference call on March 11, 2025, at 4:30 P.M. ET to provide a business update following the release of its fourth-quarter and full-year 2024 financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. A live webcast will be available on the company's website, with replay options provided for two weeks.
Monkeypox treatment trial begins in the Democratic Republic of the Congo
A clinical trial for the antiviral drug tecovirimat (TPOXX) has started in the Democratic Republic of the Congo to evaluate its safety and effectiveness in treating monkeypox in adults and children. Co-led by NIAID and the DRC's INRB, the trial seeks to mitigate symptoms and prevent severe outcomes. This initiative addresses the urgent need for improved treatment options in a region significantly affected by Clade I monkeypox virus.
U.S. warns MPX could mutate to resist antiviral drug Tpoxx
U.S. health officials caution against the overuse of Tpoxx, the only drug available to treat MPX, due to the risk of the virus mutating and rendering the medication ineffective. The FDA updated its guidance, emphasizing that even a small molecular change could significantly impact Tpoxx's antiviral activity, while the CDC advised against prescribing it to healthy adults without severe symptoms. This guidance comes as new MPX cases have fallen and officials express optimism about the outbreak's trajectory.
FDA Warns Monkeypox Could Mutate and Resist Treatment If Antiviral Drug Is Overused
The FDA has warned against the overuse of Tpoxx, the only drug available for monkeypox, due to concerns that the virus could mutate and develop resistance. This guidance comes as new monkeypox cases have fallen by about 50% since August, attributed to vaccinations and educational outreach. The agency highlighted that Tpoxx targets a single protein, making the virus susceptible to resistance through mutation, despite calls from patient groups for wider access to the drug.
Monkeypox cases drove up stock prices for these companies on Monday
Concerns over the emergence of monkeypox cases in Europe and the U.S. have led to a surge in stock prices for several vaccine and drug companies. Though typically rare outside of Central and West Africa, 92 cases have been confirmed this month in non-endemic regions. The FDA's recent approval of a new formulation of Siga's smallpox treatment is noted in relation to the rising concerns.
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
SIGA Technologies Inc. announced that the FDA has approved the intravenous (IV) formulation of TPOXX® (tecovirimat) for the treatment of smallpox. This approval provides a crucial option for patients who are unable to take the oral capsules of TPOXX, broadening access to the medication. The company highlighted its ongoing collaboration with BARDA in preparedness efforts and development of a liquid pediatric formulation.
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
SIGA Technologies announced that the European Medicines Agency (EMA) has approved its Marketing Authorisation Application (MAA) for oral tecovirimat. This approval broadens the indication to include treatments for smallpox, monkeypox, cowpox, and vaccinia complications following smallpox vaccination, enabling sales throughout the EU, Norway, Iceland, and Liechtenstein. The company views this as a crucial step for international preparedness against infectious disease outbreaks.
SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic
SIGA Technologies announced a collaboration with Oxford University to provide TPOXX® (tecovirimat) for treating monkeypox in the Central African Republic (CAR) under an expanded access protocol. SIGA will supply up to 500 courses of TPOXX at no cost, with Institut Pasteur of Bangui coordinating the study and the CAR Ministry of Health administering the treatment. This initiative aims to address the public health challenge of monkeypox in Central Africa, while SIGA also seeks to expand TPOXX's label indication to include monkeypox treatment with European Medicines Agency approval anticipated in late 2021 or early 2022.
Cipla Therapeutics, SIGA Technologies partner to address anti-microbial resistance challenge
Cipla Therapeutics and SIGA Technologies Inc have announced a partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats. This collaboration aims to address the anti-microbial resistance (AMR) challenge and provides an opportunity for US Government agencies like BARDA to advance health security initiatives with Cipla's ZEMDRI injection. The partnership leverages Cipla's commitment to AMR and SIGA's drug development and US experience.
2020 Smallpox Treatment Market Research : International Size, Growth, Trends, Outlook and Future Scope Analysis by 2025 - Emergent BioSolutions, Pfizer, SIGA Technologies
The global Smallpox Treatment Market is projected to experience significant growth, driven by increasing stockpiling of therapeutics and rising drug approvals. The market, segmented by product type (drugs, vaccines) and end-use industry (hospital, clinic), is expected to reach high values by 2024. Key players include Bavarian Nordic AS, Emergent BioSolutions Inc., Pfizer Inc., and SIGA Technologies Inc., with strategic initiatives like mergers and new product launches influencing market trends.
Lilly snaps up regulatory ‘fast pass’ for bargain price
Eli Lilly has purchased a Priority Review Voucher (PRV) from Siga Technologies for $80 million, a significantly lower price than what these "fast passes" commanded a few years prior. Siga Technologies acquired the voucher for the approval of its smallpox treatment TPOXX. This transaction highlights the declining market price of PRVs due to increased supply, but still provides a financial boost for Siga Technologies and offers Lilly a shortened drug review time for a future New Drug Application.
FDA Approves the First Drug with an Indication for Treatment of Smallpox
The FDA has approved TPOXX (tecovirimat), the first drug specifically indicated for the treatment of smallpox, to address biodefense concerns despite the disease's 1980 eradication. This approval was granted under the FDA’s Animal Rule due to the ethical infeasibility of human efficacy trials, with safety verified in healthy volunteers. TPOXX, developed by SIGA Technologies Inc. in collaboration with BARDA, received Fast Track, Priority Review, and Orphan Drug designations.
The FDA Approved an Anti-Bioterrorism Drug Meant to Treat Smallpox
The FDA approved TPOXX, the first drug specifically designed to treat smallpox, despite the disease's eradication in 1980. This approval is a safeguard against bioterrorism provided by SIGA Technologies Inc. and marks an important milestone in developing countermeasures against potential bioweapons.
PharmAthene Fulfills Anthrax Anti-Toxin Order
PharmAthene announced it has fulfilled its contract with BARDA for its anthrax anti-toxin, Valortim, as part of a government risk mitigation strategy. The biodefense company also highlighted its broader portfolio of medical countermeasures and a recent court ruling awarding them damages from SIGA Technologies, Inc. for lost profits related to SIGA's smallpox antiviral.
